FDA Approves Faslodex in Combo with Verzenio for Women with Advanced Breast Cancer

FDA Approves Faslodex in Combo with Verzenio for Women with Advanced Breast Cancer
The U.S. Food and Drug Administration (FDA) expanded to use of AstraZeneca’s Faslodex (fulvestrant) to include it in combination with Verzenio (abemaciclib) to treat HR-positive, HER2-negative advanced or metastatic breast cancer in women whose disease progressed after hormonal therapy. The approval is the result of data demonstrating that combined therapy improved progression-free patient survival by

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *